Menu
Menu
The Oncology Institute of Hope and Innovation is a leader in clinical studies, with the goal to advance the treatment of cancer. We conduct more trials than most other community cancer groups in the US. Our research helps us evaluate the effectiveness of treatment, reduce the risk of complications, lower costs and save resources, and continually refine our clinical approach to cancer care.
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis
An Open-Label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2/3 Study Of ALX148 In Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First-Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III Double-Blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase III, Open Label, Randomised, 3-Arm, Multi-urothelialCentre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up.
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Collection and Distribution of Biofluids and Tumor Tissue Biospecimens for Research Purposes
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Randomized, Non-Comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer delete ? 2 cm with Safety Run-In, Assessing Nivolumab + Palbociclib + Anastrozole (CheckMate 7A8: CHECKpoint Pathway and NivoluMAb Clinical Trial Evaluation 7A8)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab Versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients with High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAÏVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b, Multicenter, 2-Part, Open-Label Study of DS-1062a in Combination with Durvalumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations and Previously Treated with Platinum-based Chemotherapy with or without Prior Immunotherapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung01)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS 50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-LUNG08)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (DS-8201A), an Anti-HER2-Antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with T-DM1
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase (3) III, Multicenter, Randomized, A Open-Label, Active-Controlled Study of Trastuzuma Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in subjects with High-Risk Her2-Positive Primary Breast cancer who have Residual Invasive disease in Breast or axillary Lymph nodes following Neoadjuvant Therapy (T-DXd vs T-DM1 in high-risk her2-postive patients with residual invasive breast cancer following neoadjuvant therapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A long-term study to further evaluate the risk of hepatotoxicity associated with TURALIO™ (pexidartinib) treatment.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim
1707 W. St Marys Rd.
Suite 275
Tucson, AZ 85745
A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors
3300 E. South St.
Suite 304
Long Beach, CA 90805
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo In Combination with Lenalidomide plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Multicenter, Long-Term Treatment Extension Study In Subjects Who Have Completed A Prior Glaxosmithkline/Tesaro- Sponsored Niraparib Study And Are Judged By The Investigator To Benefit From Continued Treatment With Niraparib.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A randomized, open label phase 2/3 study. Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Non small Cell Lung Cancer Who Have Progressed on Prior Anti PD (L)1 Therapy and Chemotherapy (COSTAR Lung)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
900 S. Main St.
Suite 204
Corona, CA 92882
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1707 W. St Marys Rd.
Suite 275
Tucson, AZ 85745
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
A Phase 2 Clinical Study Of Tj004309 In Combination With Atezolizumab (Tecentriq®) In Patients With Advanced Or Metastatic Ovarian Cancers And Selected Advanced Solid Tumors
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory(R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Phase 3 Study of Platinum-Based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory(R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase I/II Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumors with KRasG12C Mutation.
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment.
1707 W. St Marys Rd.
Suite 275
Tucson, AZ 85745
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), PostPolycythemia Vera MF (Post-PV-MF), Or PostEssential Thrombocythemia MF (PostET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor Intolerant Myelofibrosis
900 S. Main St.
Suite 204
Corona, CA 92882
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus associated Kinase
900 S. Main St.
Suite 204
Corona, CA 92882
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
4646 Brockton Ave.
Suite 203
Riverside, CA 92506
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Double-Blind, Phase 3 Trial Of Maintenance With Selinexor/ Placebo After Combination Chemotherapy For Patients With Advanced Or Recurrent Endometrial Cancer.
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination with Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 / 2 Study to Evaluate Safety and Efficacy of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment Naive Patients with Myelofibrosis
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor versus Treatment of Physician’s Choice in Patients with Previously Treated Myelofibrosis.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
50 Bellefontaine St.
Suite 401
Pasadena, CA 91105
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Phase 3 Open-Label, Randomized Study Of LOXO-305 Versus Investigator Choice of BTK Inhibitor In Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313).
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.
900 S. Main St.
Suite 204
Corona, CA 92882
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
4646 Brockton Ave.
Suite 203
Riverside, CA 92506
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)
900 S. Main St.
Suite 204
Corona, CA 92882
4646 Brockton Ave.
Suite 203
Riverside, CA 92506
Open-Label, Multicenter, Phase IB/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients with PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU, and Anti-EGFR Containing Regimens
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
18250 Roscoe Blvd.
Suite 325
Northridge, CA 91325
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
425 Haaland Dr.
Suite 103
Thousand Oaks, CA 91361
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients with Solid Tumors Receiving Targeted-Cancer Therapies with or without Standard Chemotherapy Regimens.
900 S. Main St.
Suite 204
Corona, CA 92882
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
4646 Brockton Ave.
Suite 203
Riverside, CA 92506
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1- expressing, locally advanced or metastatic
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
LUNAR: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (NSCLC) Following Platinum Failure
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1b/2 Open-Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1, Open Label, Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants with Advanced Solid Tumors.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Phase 1/2a dose escalation and expansion study evaluating safety, tolerability, pharmacokinetic, pharmacodynamics and anti-tumor activity of pf-06873600 as a single agent and in combination with endocrine therapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-Label, Ravulizumab-Controlled Study To Evaluate The Efficacy And Safety Of Pozelimab And Cemdisiran Combination Therapy In Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive Or Have Not Recently Received Complement Inhibitor Therapy.
A Randomized, Open-Label Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with PNH Who are Currently Treated with Eculizumab or Ravulizumab
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate The Efficacy and Safety Of Adjuvant Atezolizumab Or Placebo and Trastuzumab Emtansine For Her2-Positive Breast Cancer at High Risk Of Recurrence Following Preoperative Therapy.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
Open-Label, Single-Arm Trial To Evaluate Antitumor Activity, Safety, And Pharmacokinetics Of SAR408701 Used In Combination With Ramucirumab In Metastatic, Non-Squamous, Non–Small-Cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-Positive Tumors, Previously Treated With Platinum-Based Chemotherapy And An Immune Checkpoint Inhibitor.
1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
900 S. Main St.
Suite 204
Corona, CA 92882
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-label, Nonrandomized, Phase 1 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of Belinostat in Combination with Atazanavir in Patients with Advanced Relapsed/Refractory Solid Tumors or Hematological Malignancies
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503
1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor (Arimidex, Femera), Fulvestrant and CDK 4/6 inhibitor
A Phase 2b, double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent -thalassemia.
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+)
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1/2, Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of YL-15293 in Subjects with Advanced Solid Tumors with a KRAS G12C Mutation
A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients with Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety between TRS003 and China-approved Bevacizumab Administered in Combination with Paclitaxel-Carboplatin in Subjects with Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC)
11480 Brookshire Ave.
Suite 309
Downey, CA 90241
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors.
1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033
1510 S. Central Ave.
Suite 240
Glendale, CA 91204
3300 E. South St.
Suite 304
Long Beach, CA 90805
999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
A Phase 2b, Open-Label, Single-Arm Study of ZW25 Monotherapy in Subjects with Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
3300 E. South St.
Suite 304
Long Beach, CA 90805
8135 S. Painter Ave.
Suite 103
Whittier, CA 90602
© 2022 The Oncology Institute of Hope and Innovation. All rights reserved.
English
Chinese (Simplified)
Korean
Spanish
Vietnamese